Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xueshuanxinmaining tablets
- Development stage
- Phase 4
- Lead developer
- Jilin Huakang Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xueshuanxinmaining tablets (marketed under the brand name Tianxintai) is a traditional Chinese patent medicine developed by Jilin Huakang Pharmaceutical for the treatment of cardiovascular and cerebrovascular diseases. It is formulated from ten traditional Chinese medicinal ingredients, including Ligusticum chuanxiong, Salvia miltiorrhiza, leech, holly, artificial bezoar, artificial musk, Sophora japonica, ginseng stem and leaf saponins, borneol, and toad venom. The formulation is designed to replenish qi, promote blood circulation, induce resuscitation, and relieve pain. It is primarily indicated for the recovery phase of ischemic stroke (cerebral infarction) and coronary heart disease angina pectoris characterized by qi deficiency and blood stasis.
- Brand names
- Tian Xin TaiTianxintai
- Other names
- Tian Xin Tai Xueshuanxinmaining tabletsTianxintai Xueshuanxinmaining tabletsXue Shuan Xin Mai Ning PianXueshuan XinmainingXueshuan Xinmaining tabletsXueshuanxinmainingXueshuanxinmaining PianXueshuanxinmaining tablets
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CA1 (Carbonic anhydrase 1)FXIIIa (Coagulation factor XIII A subunit)VEGFR2 (Vascular endothelial growth factor receptor 2)KEAP1 (Kelch-like ECH-associated protein 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NFKB1 (NF-κB1)SRC (Proto-oncogene tyrosine-protein kinase Src)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Xueshuanxinmaining tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xueshuanxinmaining tablets.